Webinar: Sustainable price competition – contradiction in terms?
- October 18, 2016
Payers can boast great stories of successful price competition, caused by tendering and reimbursement negotiations.
Attend this webinar by market access expert Raf De Wilde, Senior Advisor at Valid Insight, to learn:
- why companies fall into the price competition trap
- what companies can do to alleviate price competition
- what the consequences are for market access strategies and for marketing strategies.
To get a copy of the slides, please contact the team at email@example.com
Raf De Wilde, is Senior Advisor at Valid Insight. He is an expert in market access, having over 35 years’ experience in the pharmaceutical industry and 25 years in global market access.
Raf became the head of International Marketing Services within Janssen Pharmaceutica (a Johnson & Johnson (J&J) company) in 1991, introducing Health Economics at J&J that year. Raf was Chairman of EPhMRA Primary Research and Methods Committee (1993-1995). He became VP of EPhMRA in 1994 and 1997 and President in 1995 and 1998. In 1997, he joined Peter Lauper’s team, pioneering the ‘biosimilars’ concept and the first patient access schemes. Raf led a specialist oncology, real-world evidence and virology group between 2002 and 2004, where he created a centre of excellence for oncology pricing and specialised in biologics while leading the HEOR function at CENTOCOR. Raf was VP of Market Access at J&J leading teams working on oncology, cardiovascular and biotech products from 2004 to 2010. Raf then joined United Biosource Corporation (UBC) as Associate VP in early 2011 and stayed with Evidera until 2015. In his consulting career he has led over 100 global market access projects, including value strategies, price finding research, patient access schemes, negotiation tactics, tendering and contracting, WHO classification and naming strategies. He has moderated over 100 training workshops in Asia, Asia-Pacific, Europe, North America and Middle-East.